Core AI Holdings Reports Strong Operational Execution Across AI Products, Data Intelligence and Growth Initiatives

Miami, FL, Aug. 06, 2026 (GLOBE NEWSWIRE) — Core AI Holdings, Inc. (Nasdaq: CHAI) (“Core AI” or the “Company”), a global AI technology and infrastructure company, today highlighted strong operational execution across its AI product portfolio, data intelligence initiatives and digital distribution platform. During the first half of 2026, the Company advanced multiple product milestones ahead of schedule, accelerated user acquisition across its gaming portfolio, expanded its internal AI-driven analytics capabilities and continued to deploy capital through a disciplined, performance-based operating model that emphasizes measurable validation before scaling investment.

Pasqal F-4 Declared Effective by SEC in Connection with Proposed Business Combination with Bleichroeder Acquisition Corp. II

PARIS and NEW YORK , Aug. 06, 2026 (GLOBE NEWSWIRE) — Pasqal Holding SAS (“Pasqal”), a global leader in neutral-atom quantum computing, today announced that its joint registration statement on Form F-4 (the “Registration Statement”) with Bleichroeder Acquisition Corp. II (Nasdaq: BBCQ) (“Bleichroeder”), filed with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the proposed business combination between Pasqal and Bleichroeder, has been declared effective by the SEC on August 5, 2026. This milestone represents an important step toward completion of the previously announced business combination between Pasqal and Bleichroeder.

Rocket Doctor AI Inc. Announces Closing of Oversubscribed First Tranche of Unsecured Convertible Debenture Financing

Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States

Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States

XM launches GOLD24-7, bringing weekend gold trading to its clients

LIMASSOL, Cyprus, Aug. 06, 2026 (GLOBE NEWSWIRE) — XM has introduced GOLD24-7, a new Gold trading instrument that gives traders access to Gold markets seven days a week.  
Unlike traditional Gold CFDs, which follow standard market hours, GOLD24-7 allows traders to continue trading Gold over the weekend.
“Markets don’t stop generating news simply because it’s the weekend,” said Stavri Morti, Co-CEO at XM. “Economic data, geopolitical developments and breaking news can all influence market sentiment over the weekend. We introduced GOLD24-7 to give our clients greater flexibility to respond to those developments as they happen, instead of waiting until Monday.”
The launch forms part of XM’s broader strategy to expand its product offering while continuing to evolve its trading experience in line with changing market conditions and client needs. 
For over 15 years, XM has been a market leader in Gold trading. This position was further solidified earlier this year amid historic volatility in the gold market, as the broker provided traders with uninterrupted trading and exceptional execution conditions, including zero requotes and no rejections. GOLD24-7 builds on that approach by extending Gold trading beyond the traditional trading week.  
GOLD24-7 is now available to all XM clients. Traders interested in accessing the new instrument can open an XM account in just minutes to begin trading Gold throughout the week. 
#XMGOLD247Trading
About XM 
XM is an internationally established trading and investment firm, with over 20 million clients, from over 190 countries. Armed with multiple international licenses, XM offers competitive services for retail traders, investors, and affiliates.  
With over 15 years of serving clients, XM has proven to be fair, trustworthy, and dependable. Traders can access over 1,400 instruments across all devices. The award-winning broker is known for its wide range of products, excellent support, and outstanding education. 
Risk Warning: Trading involves significant risks and may result in the loss of your invested capital. T&Cs apply 
Disclaimer: Promotions and bonuses are not available for accounts registered under XM’s EU-based entity. Specific regions may be excluded. The XM Group operates globally under various entities, so products, services, and features listed here vary between XM entities. For further information, please visit the XM website.  

Healthcare Chatbots Market Size to Hit USD 11.13 Billion by 2035 Driven by Generative AI and Virtual Healthcare Adoption | SNS Insider

The U.S. market is projected to reach USD 3.17 Billion by 2035, while Europe is expected to hit USD 2.91 Billion, fueled by EHR integration, clinician shortages, and growing AI-powered patient engagement.

The U.S. market is projected to reach USD 3.17 Billion by 2035, while Europe is expected to hit USD 2.91 Billion, fueled by EHR integration, clinician shortages, and growing AI-powered patient engagement.

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the U.S., China, and Taiwan, with marketing authorization applications pending in other countries.